1. Home
  2. ZH vs ALT Comparison

ZH vs ALT Comparison

Compare ZH & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ZH
  • ALT
  • Stock Information
  • Founded
  • ZH 2011
  • ALT 1997
  • Country
  • ZH China
  • ALT United States
  • Employees
  • ZH N/A
  • ALT N/A
  • Industry
  • ZH Business Services
  • ALT Biotechnology: Pharmaceutical Preparations
  • Sector
  • ZH Consumer Discretionary
  • ALT Health Care
  • Exchange
  • ZH Nasdaq
  • ALT Nasdaq
  • Market Cap
  • ZH 365.1M
  • ALT 292.0M
  • IPO Year
  • ZH 2021
  • ALT N/A
  • Fundamental
  • Price
  • ZH $4.81
  • ALT $3.83
  • Analyst Decision
  • ZH Strong Buy
  • ALT Strong Buy
  • Analyst Count
  • ZH 1
  • ALT 6
  • Target Price
  • ZH $4.70
  • ALT $17.40
  • AVG Volume (30 Days)
  • ZH 390.5K
  • ALT 3.0M
  • Earning Date
  • ZH 08-27-2025
  • ALT 08-12-2025
  • Dividend Yield
  • ZH N/A
  • ALT N/A
  • EPS Growth
  • ZH N/A
  • ALT N/A
  • EPS
  • ZH 0.22
  • ALT N/A
  • Revenue
  • ZH $439,821,184.00
  • ALT $20,000.00
  • Revenue This Year
  • ZH N/A
  • ALT N/A
  • Revenue Next Year
  • ZH $7.46
  • ALT $761,880.20
  • P/E Ratio
  • ZH $21.62
  • ALT N/A
  • Revenue Growth
  • ZH N/A
  • ALT N/A
  • 52 Week Low
  • ZH $3.13
  • ALT $2.90
  • 52 Week High
  • ZH $6.32
  • ALT $11.16
  • Technical
  • Relative Strength Index (RSI)
  • ZH 56.37
  • ALT 51.79
  • Support Level
  • ZH $4.58
  • ALT $3.35
  • Resistance Level
  • ZH $5.01
  • ALT $3.66
  • Average True Range (ATR)
  • ZH 0.28
  • ALT 0.19
  • MACD
  • ZH 0.02
  • ALT 0.07
  • Stochastic Oscillator
  • ZH 55.91
  • ALT 86.18

About ZH Zhihu Inc. (every two of each representing one ordinary share)

Zhihu Inc is predominantly engaged in the operation of one online content community and monetizes through paid membership services, advertising services, content-commerce solutions services, and vocational training in China. It generates revenues from Advertising services, Paid membership services, Content-commerce solutions, and Others. It derives all its revenues within China.

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Share on Social Networks: